Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical develops and distributes the LIBERTY Endovascular Robotic System, an FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. Company news centers on the system’s U.S. commercialization, adoption by healthcare institutions, use across peripheral endovascular case types, and clinical evidence from the ACCESS-PVI pivotal study.
Updates also cover medical-society guidance on radiation exposure and ergonomics in interventional radiology, conference presentations to healthcare and financial audiences, and commercial readiness outside the United States. The company frames LIBERTY around robotic vascular navigation and the need to address radiation exposure and physical strain for interventional teams.
Microbot Medical (Nasdaq: MBOT) will participate in the Society of Robotic Surgery annual meeting in Fort Lauderdale, FL, from July 23-26, 2026, showcasing its LIBERTY Endovascular Robotic System within the conference’s focus on novel robotic technologies and digital surgery applications.
The company highlights that endovascular robotics was first featured at SRS last year and notes its FDA clearance for LIBERTY less than a year ago, alongside growing adoption at leading U.S. academic centers for peripheral endovascular procedures. A panel titled “Neurovascular Robotics” will be held on Saturday, July 25, at 9:50am ET, moderated by Dr. Adnan Siddiqui. CEO, President and Chairman Harel Gadot will present an overview of the endovascular robotic market at 10:25am ET, livestreamed via the SRS 2026 platform. Microbot Medical will appear with other medical robotics companies covering peripheral vascular, neurovascular and cardiovascular technologies, and notes that LIBERTY recently received the Innovative Start-Up Award from Surgical Robotics Technology.
Microbot Medical (Nasdaq: MBOT) reported greater than 100% quarter-over-quarter growth in revenue and new customers for Q2 2026 following the Full Market Release of the LIBERTY Endovascular Robotic System on April 13, 2026.
The company expanded U.S. sales territories from 4 to 8, plans 12 by year-end, signed a distribution agreement with Lovell Government Services for federal healthcare systems, gained marketing clearance in Israel, and agreed to establish a second manufacturing site to support demand and potential margin expansion.
Microbot Medical (Nasdaq: MBOT) signed a Letter of Agreement with Sanmina to manufacture the LIBERTY Endovascular Robotic System, the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures.
The deal adds a second manufacturing site, aimed at boosting capacity, supporting global expansion, and, according to Microbot, improving operating efficiencies, lowering costs, and expanding gross margins as LIBERTY adoption grows in the U.S. and internationally.
Microbot Medical (Nasdaq: MBOT) announced that its LIBERTY® Endovascular Robotic System won the Innovative Start-Up Award from Surgical Robotics Technology for 2026.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures and is used at leading academic centers across NY, PA, FL, GA, MA, MI, and NC.
The company reports continued adoption and utilization since the full market release in early April, viewing the award as validation of LIBERTY’s role in advancing robotic-assisted endovascular care.
Microbot Medical (Nasdaq: MBOT) announced that a globally recognized academic health system headquartered in Pennsylvania is the first in the state to adopt the LIBERTY Endovascular Robotic System. This customer operates multiple hospitals and multispecialty centers across Pennsylvania and New Jersey.
Microbot Medical now has LIBERTY accounts spanning seven Eastern U.S. states, following its transition to full market release in the second quarter, and plans to expand sales to the West Coast. An agreement to expand access across certain U.S. federal healthcare systems, including those serving veterans and military patients, is intended to support accelerated adoption.
Microbot Medical (Nasdaq: MBOT) signed an agreement with Lovell Government Services, a Service-Disabled Veteran-Owned Small Business vendor, to expand access to the LIBERTY Endovascular Robotic System across federal healthcare systems.
The LIBERTY System is expected to be added to Lovell’s Federal Supply Schedule in Q3 2026 and listed on major federal procurement platforms, potentially reaching over 2,000 government facilities, including VHA, MHS, and IHS sites.
Microbot Medical (Nasdaq: MBOT) announced that one of the largest healthcare systems in Michigan is the first in Michigan and the broader Midwest to adopt the LIBERTY Endovascular Robotic System. This follows the company’s first healthcare system customer in North Carolina.
The adoption supports Microbot’s full market release strategy and reflects growing interest in robotic peripheral endovascular procedures, a U.S. market of about 2.5 million annual procedures. LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for these procedures and recently received regulatory approval for sale in Israel.
Microbot Medical (Nasdaq: MBOT) announced its first North Carolina-based customer for the LIBERTY Endovascular Robotic System. This leading academic healthcare system, operating a multi-hospital network across the state, becomes the first user in the Southeast/Mid-Atlantic region and adds to a growing roster of adopting health systems.
Microbot Medical (Nasdaq: MBOT) received its first international regulatory approval for commercializing the LIBERTY Endovascular Robotic System in Israel.
The Israeli Ministry of Health’s AMAR Division clearance enables marketing in Israel and supports obtaining a Free Sale Certificate for submissions and commercial activities in additional global jurisdictions.
Microbot Medical (Nasdaq: MBOT) will host an analysts and investors conference call and webcast on Monday, May 18 at 3:00pm ET. The event will review progress of the Full Market Release of the LIBERTY Endovascular Robotic System and address recent misrepresentations from an unaffiliated third-party article.
Executives will be joined by current LIBERTY users Dr. Charles Briggs and Dr. Zachary Bercu, who will discuss real-world clinical experience and clarify statements previously attributed to them.